Full Press Release Details
IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ 11 Tumors and Preclinical MAT2A Synthetic Lethality Program.
IDYA
IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ 11 Tumors and Preclinical MAT2A Synthetic Lethality Program
Key Takeaway: IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ 11 Tumors and Preclinical MAT2A Synthetic Lethality Program
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma